Dyadic International Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered approval of all shareholder proposals, including a reverse stock split and director election. Strategic updates highlighted commercial growth, new partnerships, and ongoing Nasdaq compliance efforts. Shareholders were invited to participate in a Q&A session.
-
Transitioning to a commercial stage, the company has launched six products in the past year and established global distribution and key partnerships, driving early revenues across life sciences, food, and bioindustrial markets. Recurring revenues and further launches are expected in 2026.
-
The company has transitioned to a product-driven model, commercializing six animal-free protein products across life sciences, food nutrition, and bioindustrial markets. Strategic partnerships, scalable platforms, and a diversified revenue model support rapid growth, with recurring revenues expected to accelerate as products move from pilot to commercial scale.
-
Revenue grew 182% year-over-year to $1.1 million, driven by product launches and expanded partnerships. Loss from operations improved, and cash runway extends into Q2 2027. Commercial momentum is building across life sciences, food, and industrial segments.
-
Transitioning from R&D to commercial operations, the company has launched multiple products in life sciences, food, and bioindustrial markets, leveraging its C1 and Dapibus platforms. Strategic partnerships and direct sales are driving early revenues, with significant growth expected from late 2026 as more products and collaborations mature.
Fiscal Year 2025
-
Transitioned to a commercial-stage biotech with new product launches and expanded partnerships, though 2025 revenue declined to $3.09M and net loss widened. Expecting revenue growth in 2026, with cash runway into 2027 and a focus on recurring revenue streams.
-
A commercial inflection point is underway, with multiple animal-free protein products launching across life sciences, food nutrition, and bio-industrial markets. Strategic partnerships, rapid product development, and a layered revenue model are expected to drive growth and achieve cash flow positivity at a $12 million run rate.
-
Q3 2025 marked a pivotal shift to commercial operations, with first bulk protein sales, expanded product launches, and global partnerships. Revenue declined year-over-year, but cash position strengthened and product revenue growth is expected in late 2025 and 2026.
-
A strategic shift to non-therapeutic, high-growth markets is driving rapid commercialization and revenue generation, with validated platforms and key partnerships enabling product launches in life sciences, food, and bioindustrial sectors. Cash flow positivity is targeted by end of 2026, with profitability expected within three years.
-
Q2 2025 saw revenue more than double year-over-year, driven by milestone and grant income, while net loss narrowed. The company completed a $5.3 million equity raise, advanced commercial launches across life sciences, food, and bioindustrial segments, and targets profitability by end of 2026.
-
Q1 2025 saw a strategic pivot to commercializing high-value, non-pharmaceutical proteins and enzymes, with revenue up 18% year-over-year and imminent product launches in cell culture media and animal-free dairy. Cash reserves remain strong, and immediate revenue sharing from new industrial enzyme contracts is underway.
Fiscal Year 2024
-
Revenue grew 21% year-over-year, driven by licensing and enzyme sales, while net loss narrowed and R&D expenses declined. Multiple commercial launches are targeted for 2025, supported by major grants and expanding partnerships in alternative proteins, life sciences, and bio-industrials.
-
Q3 2024 revenue surged year-over-year, driven by licensing and milestone payments, while operating losses narrowed and cash reserves grew. Strategic partnerships and product launches in alternative proteins and biopharma are accelerating, with new research-grade products and commercial launches expected in 2025.
-
Q2 2024 saw lower revenue due to winding down of collaborations, but new partnerships in alternative proteins, cell culture, and bioindustrial enzymes are expected to drive future growth. Strategic deals, notably with Proliant, and a strong cash position support commercialization plans.